AOD9604 in sport: fat-loss claims, negative trials and risks

Why the idea appealed to physique sport

AOD9604 is discussed as a fragment intended to separate a proposed fat-metabolism effect from the wider effects of growth hormone. That story is attractive to people seeking a leaner appearance without an appetite-focused medicine. The central issue is whether it worked in people, not whether the molecular design sounds selective. A sports article should also ask whether any observed change improves function or preserves health. Naming a fragment after an anti-obesity development programme does not turn it into an effective or appropriate sporting intervention.

The molecule is not simply interchangeable with HGH Frag

AOD9604 is a modified C-terminal growth-hormone-derived peptide, often described as Tyr-hGH 177–191. Products labelled HGH fragment 176–191 should not automatically be treated as the same tested material. Small sequence changes can matter to identity, stability and biological behaviour. Nor can findings for a fragment be borrowed from full-length growth hormone. Claims about muscle building, fat mobilisation and metabolic safety each need evidence for the actual molecule and the relevant formulation, rather than a resemblance between names.

What the named research shows

Heffernan and colleagues' 2001 Endocrinology study found changes in fat metabolism in obese mice and used beta-3-adrenoceptor knockout animals to investigate mechanism. It provided a preclinical hypothesis, not a human sports result.

Stier, Vos and Kenley's 2013 Journal of Endocrinology and Metabolism report summarised safety observations from six human trials. Its focus was tolerability and growth-hormone-related laboratory measures, not a full demonstration of weight-loss efficacy. The FDA's December 2024 review described the OPTIONS study, with 502 randomised adults, and no significant weight-loss difference from placebo at its primary endpoint. The negative human result is directly relevant when early animal findings are used to advertise fat loss.

Potential advantages need to survive a clinical test

The proposed advantage was a more selective metabolic effect with fewer of the concerns associated with the intact hormone. That is a development objective, not an established product benefit. A negative efficacy result cannot be repaired by pointing to a safety measure or a subgroup anecdote. For sport, there is also no established performance, muscle-preservation or recovery benefit in the studies cited here. Even a result showing no change in one laboratory marker would not answer those separate questions.

Safety: limited evidence is not a clean bill of health

The safety report should be read alongside the limitations of the datasets and formulations. FDA separately highlights uncertainty concerning AOD-9604 safety, immunogenicity, peptide-related impurities and product characterisation; it also notes serious events with uncertain causality. This does not establish that every event was caused by the molecule, but it makes a blanket risk-free claim inappropriate. Adverse effects of an unverified product may also arise from identity or quality problems that are not captured by the original research material.

Anti-doping and the conclusion for athletes

The WADA 2026 Prohibited List explicitly names AOD-9604 among growth-hormone fragments in S2. It is prohibited in and out of competition. This is a sporting rule, separate from whether a substance works or is medically suitable. The evidence reviewed here does not justify a sporting application plan or a fat-loss promise. The important lesson is to retain negative findings in the account: an appealing mechanism and reassuring selected safety measurements do not outweigh a failed clinical efficacy question.